EU/3/10/726

Table of contents

About

On 23 March 2010, orphan designation (EU/3/10/726) was granted by the European Commission to Protalix B.V., the Netherlands, for taliglucerase alfa for the treatment of Gaucher disease.

The sponsorship was transferred to Pfizer Limited, United Kingdom, in September 2010 and subsequently to Pfizer Europe MA EEIG, Belgium, in November 2018.

Key facts

Active substance
Taliglucerase alfa
Disease / condition
Treatment of Gaucher disease
Date of first decision
23/03/2010
Outcome
Positive
EU designation number
EU/3/10/726

Sponsor's contact details

Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium
Tel. +32 2554 6586
E-mail: orphan_enquiries@pfizer.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating